International Forum on Home‐Based Blood Transfusion: Summary

Shaw, Briony; Wood, Erica M.; McQuilten, Zoe; Callum, Jeannie; Romón, Íñigo; Sanroma, Pedro; García, D. Morales; Crispin, Philip; Castilho, Lilian; Kutner, José Mauro; Yokoyama, Ana Paula Hitomi; Bravo, Amalia; Sanchez, Emmanuel Fernandez; Silva, Karla Maldonado; Arora, Satyam; Radhakrishnan, Nita; Dua, Seema; Ziman, Alyssa; Wikman, Agneta; Lübenow, Norbert; Zingmark, Linda Bodecker; Louw, Vernon; Loebenberg, Perry; Sidhu, Davinder; Redfern, Tara; Nahirniak, Susan; Dunbar, Nancy M.

doi:10.1111/vox.13200

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Out‐of‐hospital transfusion has been in practice for many years in different locations, such as patients' homes, hospices and rehabilitation facilities, and in a variety of patients of different ages and diagnoses [ 21 ]. Different reports showed that HT is feasible and safe when performed on selected patients by trained staff under specific protocols [ 22 , 23 , 24 ]. The main advantage of this practice is facilitating CCP administration early in the disease course, perhaps before the patients develop their own antibodies.…”

Section: Discussionmentioning

confidence: 99%

Early and out‐of‐hospital use of COVID‐19 convalescent plasma: An international assessment of utilization and feasibility

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background and Objectives: The use of coronavirus disease 2019 convalescent plasma (CCP) in the treatment of patients with severe acute respiratory syndrome-2 infection has been controversial. Early administration of CCP before hospital admission offers a potential advantage. This manuscript summarizes current trials of early use of CCP and explores the feasibility of this approach in different countries.Materials and Methods: A questionnaire was distributed to the International Society of Blood Transfusion (ISBT) CCP working group. We recorded respondents' input on existing trials on early/outpatient CCP and out-of-hospital (OOH)/home transfusion (HT) practices in their countries and feedback on challenges in initiating home CCP infusion programmes. In addition, details of existing trials registered on clinicaltrials.gov were summarized.Results: A total of 31 country representatives participated. Early/OOH CCP transfusion studies were reported in the United States, the Netherlands, Spain and Brazil. There were a total of six published and five ongoing trials on the prophylactic and therapeutic early use of CCP. HT was practised in Australia, the UK,

show abstract

Section: Discussionmentioning

confidence: 99%

Early and out‐of‐hospital use of COVID‐19 convalescent plasma: An international assessment of utilization and feasibility

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The current practice of blood product administration is almost exclusive to the hospital setting. Although home transfusion services are available in some countries, logistic and safety concerns limit their use [8]. The accelerated shift in healthcare delivery during the COVID‐19 pandemic could potentially promote the development of home transfusion units worldwide.…”

Section: Introductionmentioning

confidence: 99%

Haematological patients' perception of home transfusions: Effect of the COVID‐19 pandemic

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: The COVID-19 pandemic has led to a growing interest in hospital-at-home programmes, including home transfusion services. We studied whether the pandemic had influenced patients' perception of home transfusions. Materials and Methods:We conducted a survey among haematology patients who receive transfusions in the hospital day care facility. Patients were asked about the burden of day care transfusions and whether they would prefer receiving home transfusions. The survey was conducted during the COVID-19 pandemic, and the results were compared with a survey performed before the pandemic (baseline).Results: Sixty patients were included in the COVID-19 cohort and 31 patients in the baseline cohort. There was a non-significant decrease in the proportion of patients willing to receive home transfusions during the pandemic compared with baseline (35% vs. 47%, respectively, p = 0.28). More patients in the COVID-19 cohort were afraid to receive home transfusions (60% compared with 48% at baseline, p = 0.29), and fewer patients believed that hospital transfusion impaired their quality of life (19% compared with 36% at baseline, p = 0.09). These unexpected results may be partly attributed to the shorter time needed to arrive at the hospital during the pandemic and a greater fear of having transfusion-related adverse effects at home. Conclusions:Our results show that the pandemic did not increase the willingness of patients to receive home transfusions, with a non-significant drift towards refusal of home transfusions. Patients' opinions should be taken into consideration when planning for future home transfusion services, by creating a comprehensive approach to patients' needs.

show abstract